【4-9　メタアナリシス】

| CQ | 手術可能な浸潤性乳癌に対して術前化学療法は推奨されるか？ | | |
|---|---|---|---|
| **P** 手術可能な浸潤性乳癌 | | **I** 術前化学療法 | |
| **C** 術後化学療法 | | **O** 無病生存期間の改善 | |

| 研究デザイン | RCT | 文献数 | 10 | コード | Bordeaux 1991, ECTO 2005, EORTC 2001, Institut Curie 1994, Japan 1998, Lithania1998, NSABP 1998, Royal Marsden 1998, St. Petersburg 1994, USA 2003 |
|---|---|---|---|---|---|
| **モデル** | ランダム効果 | | **方法** | | Cochrane Review Manager Software (RevMan 4.2) |
| **効果指標** | オッズ比 | **統合値** | | 0.97 ( 0.89 － 1.07 ) P= 0.58 | |

**Forest plot**



| Study or subgroup | Treatment n/N | Control n/N | Peto Odds Ratio Exp[(O-E)/V],Fixed,95% CI | Weight | Peto Odds Ratio Exp[(O-E)/V],Fixed,95% CI |
|---|---|---|---|---|---|
| Bordeaux 1991 | 57/134 | 54/138 | | 7.0 % | 1.05 [ 0.74, 1.50 ] |
| ECTO 2005 | 78/451 | 63/451 | | 7.9 % | 1.22 [ 0.88, 1.70 ] |
| EORTC 2001 | 172/350 | 160/348 | | 19.1 % | 1.12 [ 0.90, 1.39 ] |
| Institut Curie 1994 | 82/200 | 86/190 | | 16.6 % | 0.91 [ 0.72, 1.15 ] |
| Japan 1998 | 2/20 | 10/25 | | 0.5 % | 0.30 [ 0.08, 1.17 ] |
| Lithuania 1998 | 1/50 | 4/50 | | 0.3 % | 0.33 [ 0.06, 1.88 ] |
| NSABP 1998 | 323/742 | 338/751 | | 37.5 % | 0.95 [ 0.82, 1.11 ] |
| Royal Marsden 1998 | 42/144 | 41/142 | | 6.6 % | 1.00 [ 0.70, 1.44 ] |
| St. Petersburg 1994 | 26/137 | 38/134 | | 3.5 % | 0.60 [ 0.36, 0.99 ] |
| USA 2003 | 8/26 | 11/27 | | 1.1 % | 0.58 [ 0.23, 1.44 ] |
| **Total (95% CI)** | | | | 100.0 % | **0.97 [ 0.89, 1.07 ]** |

Heterogeneity: Chi² = 13.32, df = 9 (P = 0.15); I² =32%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable

コメント：　一つの使用例数の少ないRCTにおいて有意な差を認めているが他は認めておらず、全体としては有意な差は認めておらず、信頼区間も狭い。

**Funnel plot**



コメント：　症例数の少ないRCTで高い効果を認めており、全体で異質性を認めている（I² =32.5%;P,0.15)）

| その他の解析 | | コメント： |
|---|---|---|
| メタリグレッション | | |
| 感度分析 | | |

【4-9 メタアナリシス】

| CQ | 手術可能な浸潤性乳癌に対して術前化学療法は推奨されるか？ | | |
|---|---|---|---|
| P | 手術可能な浸潤性乳癌 | I | 術前化学療法 |
| C | 術後化学療法 | O | 全生存期間の改善 |

| 研究デザイン | RCT | 文献数 | 10 | コード | Bordeaux 1991, ECTO 2005, EORTC 2001, Institut Curie 1994, Japan 1998, London 2001, NSABP 1998, Royal Marsden 1998, St. Petersburg 1994, USA 2003 |
|---|---|---|---|---|---|
| モデル | ランダム効果 | | 方法 | | Cochrane Review Manager Software（RevMan 4.2） |
| 効果指標 | オッズ比 | | 統合値 | | 0.98（　　0.87　−　　1.09　）P=　　0.67 |

**Forest plot**



| Study or subgroup | Treatment n/N | Control n/N | Peto Odds Ratio Exp[(O-E)/V],Fixed,95% CI | Weight | Peto Odds Ratio Exp[(O-E)/V],Fixed,95% CI |
|---|---|---|---|---|---|
| Bordeaux 1991 | 48/134 | 51/138 | | 7.6 % | 0.99 [ 0.65, 1.51 ] |
| ECTO 2005 | 32/451 | 30/451 | | 5.4 % | 1.06 [ 0.64, 1.74 ] |
| EORTC 2001 | 111/350 | 104/348 | | 18.6 % | 1.09 [ 0.83, 1.42 ] |
| Institut Curie 1994 | 55/200 | 60/190 | | 9.6 % | 0.79 [ 0.54, 1.15 ] |
| Japan 1998 | 3/20 | 3/25 | | 0.5 % | 1.61 [ 0.29, 8.99 ] |
| London 2001 | 27/100 | 21/110 | | 2.9 % | 1.21 [ 0.61, 2.39 ] |
| NSABP 1998 | 221/742 | 218/751 | | 40.2 % | 1.02 [ 0.85, 1.22 ] |
| Royal Marsden 1998 | 43/144 | 53/142 | | 12.4 % | 0.81 [ 0.58, 1.13 ] |
| St. Petersburg 1994 | 20/137 | 30/134 | | 2.6 % | 0.88 [ 0.43, 1.79 ] |
| USA 2003 | 3/26 | 6/27 | | 0.4 % | 0.18 [ 0.03, 1.19 ] |
| **Total (95% CI)** | | | | 100.0 % | 0.98 [ 0.87, 1.09 ] |

Heterogeneity: Chi² = 7.26, df = 9 (P = 0.61); I² =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable

0.1　0.2　0.5　1　2　5　10
Favours treatment　　Favours control

コメント：　すべてのRCTにおいて有意な差は認めていない

**Funnel plot**



コメント：　一つの症例数の少ないRCTで高い効果を認めているが、全体で異質性は認めていない

| その他の解析 | | コメント： |
|---|---|---|
| メタリグレッション | | |
| 感度分析 | | |

【4-9 メタアナリシス】

| CQ | 手術可能な浸潤性乳癌に対して術前化学療法は推奨されるか？ | | | |
|---|---|---|---|---|
| P | 手術可能な浸潤性乳癌 | | I | 術前化学療法 |
| C | 術後化学療法 | | O | 局所再発率の増加 |
| 研究デザイン | RCT | 文献数 | 10 | コード | Bordeaux 1991, ECTO 2005, EORTC 2001, Institut Curie 1991, Institut Curie 1994, Japan 1998, Lithuania 1998, London 2001, NSABP 1998, Royal Marsden 1998, USA 2003 |
| モデル | ランダム効果 | 方法 | | Cochrane Review Manager Software (RevMan 4.2) |
| 効果指標 | オッズ比 | 統合値 | | 1.21（  1.02 － 1.43 ）P=  0.025 |

**Forest plot**

| Study or subgroup | Treatment n/N | Control n/N | Peto Odds Ratio Exp[(O-E)/V],Fixed,95% CI | Weight | Peto Odds Ratio Exp[(O-E)/V],Fixed,95% CI |
|---|---|---|---|---|---|
| Bordeaux 1991 | 31/134 | 12/138 | | 7.8 % | 2.57 [ 1.41, 4.67 ] |
| ECTO 2005 | 8/438 | 22/875 | | 5.4 % | 0.75 [ 0.37, 1.53 ] |
| EORTC 2001 | 49/350 | 44/348 | | 16.8 % | 1.16 [ 0.77, 1.74 ] |
| Institut Curie 1991 | 17/95 | 17/86 | | 6.1 % | 0.90 [ 0.46, 1.76 ] |
| Institut Curie 1994 | 49/200 | 37/190 | | 15.2 % | 1.31 [ 0.86, 2.01 ] |
| Japan 1998 | 2/20 | 3/25 | | 0.9 % | 0.83 [ 0.14, 4.76 ] |
| Lithuania 1998 | 1/50 | 3/50 | | 0.7 % | 0.38 [ 0.05, 2.69 ] |
| London 2001 | 24/100 | 20/110 | | 5.2 % | 1.21 [ 0.58, 2.52 ] |
| NSABP 1998 | 108/742 | 96/751 | | 36.9 % | 1.15 [ 0.87, 1.51 ] |
| Royal Marsden 1998 | 13/144 | 9/142 | | 4.0 % | 1.50 [ 0.65, 3.45 ] |
| USA 2003 | 3/26 | 2/27 | | 0.9 % | 1.58 [ 0.27, 9.11 ] |
| **Total (95% CI)** | | | | 100.0 % | 1.21 [ 1.02, 1.43 ] |

Heterogeneity: Chi² = 10.76, df = 10 (P = 0.38); I² =7%
Test for overall effect Z = 2.24 (P = 0.025)
Test for subgroup differences: Not applicable

0.1 0.2 0.5 1 2 5 10
Favours treatment   Favours control

コメント：　全体では有意に局所再発率が高いが、3つの試験では非切除や放射線治療にばらつきがあるため、それらを除外すると局所再発率に差はなくなる（別の解析を参照）

**Funnel plot**

SE(log Peto OR)

Peto OR (IPD)

コメント：　symmetrical distributionで異質性なし

<table>
<tr><td colspan="5">3つの試験を除外した場合<br>HR 1.12 (95% CI, 0.92 to 1.37; P, 0.25)<br>heterogeneity (I2, 0%; P, 0.86),<br>representing a risk difference of 2.6% (95% CI,1.3 to 3.9; control group risk,<br>8.6%; NNH, 39)</td><td>コメント:</td></tr>
</table>

| Study or subgroup | Treatment n/N | Control n/N | Peto Odds Ratio Exp[(O-E)/V],Fixed,95% CI | Weight | Peto Odds Ratio Exp[(O-E)/V],Fixed,95% CI |
|---|---|---|---|---|---|
| **1 Included** | | | | | |
| ECTO 2005 | 8/438 | 22/875 | | 7.7 % | 0.75 [ 0.37, 1.53 ] |
| EORTC 2001 | 49/350 | 44/348 | | 23.7 % | 1.16 [ 0.77, 1.74 ] |
| Japan 1998 | 2/20 | 3/25 | | 1.3 % | 0.83 [ 0.14, 4.76 ] |
| Lithuania 1998 | 1/50 | 3/50 | | 1.0 % | 0.38 [ 0.05, 2.69 ] |
| London 2001 | 24/100 | 20/110 | | 7.3 % | 1.21 [ 0.58, 2.52 ] |
| NSABP 1998 | 108/742 | 96/751 | | 52.1 % | 1.15 [ 0.87, 1.51 ] |
| Royal Marsden 1998 | 13/144 | 9/142 | | 5.7 % | 1.50 [ 0.65, 3.45 ] |
| USA 2003 | 3/26 | 2/27 | | 1.3 % | 1.58 [ 0.27, 9.11 ] |
| **Subtotal (95% CI)** | **1870** | **2328** | | **100.0 %** | **1.12 [ 0.92, 1.37 ]** |
| Heterogeneity: Chi² = 3.22, df = 7 (P = 0.86); I² =0.0% | | | | | |
| Test for overall effect: Z = 1.15 (P = 0.25) | | | | | |
| **2 Excluded** | | | | | |
| Bordeaux 1991 | 31/134 | 12/138 | | 26.7 % | 2.57 [ 1.41, 4.67 ] |
| Institut Curie 1991 | 17/95 | 17/86 | | 21.1 % | 0.90 [ 0.46, 1.76 ] |
| Institut Curie 1994 | 49/200 | 37/190 | | 52.3 % | 1.31 [ 0.86, 2.01 ] |
| **Subtotal (95% CI)** | **429** | **414** | | **100.0 %** | **1.45 [ 1.06, 1.97 ]** |
| Heterogeneity: Chi² = 5.67, df = 2 (P = 0.06); I² =65% | | | | | |
| Test for overall effect: Z = 2.36 (P = 0.018) | | | | | |
| Test for subgroup differences: Chi² = 1.86, df = 1 (P = 0.17), I² =46% | | | | | |

0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control

その他の解析

メタリグレッション

感度分析

【4-9　メタアナリシス】

| CQ | | 手術可能な浸潤性乳癌に対して術前化学療法は推奨されるか？ | | |
|---|---|---|---|---|
| P | 手術可能な浸潤性乳癌 | | I | 術前化学療法 |
| C | 術後化学療法 | | O | 血液毒性 |
| 研究デザイン | RCT | 文献数 | 4 コード | Bordeaux 1991，EORTC 2001，Institut Curie 1994，NSABP 1998， |
| モデル | ランダム効果 | 方法 | | Cochrane Review Manager Software（RevMan 4.2） |
| 効果指標 | リスク比 | 統合値 | | 0.69（　0.56　−　0.84　）P=　0.00030 |



Forest plot

| Study or subgroup | Treatment n/N | Control n/N | Risk Ratio M-H,Fixed,95% CI | Weight | Risk Ratio M-H,Fixed,95% CI |
|---|---|---|---|---|---|
| 1 Postoperative complications | | | | | |
| Edinburgh 1995 | 7/40 | 7/39 | | 52.4 % | 0.98 [ 0.38, 2.52 ] |
| EORTC 2001 | 0/350 | 2/348 | | 18.5 % | 0.20 [ 0.01, 4.13 ] |
| USA 2003 | 4/26 | 4/27 | | 29.0 % | 1.04 [ 0.29, 3.72 ] |
| Subtotal (95% CI) | 416 | 414 | | 100.0 % | 0.85 [ 0.41, 1.76 ] |

Total events: 11 (Treatment), 13 (Control)
Heterogeneity: Chi² = 1.06, df = 2 (P = 0.59); I² =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)

| 2 Cardiotoxicity | | | | | |
|---|---|---|---|---|---|
| ECTO 2005 | 50/451 | 66/451 | | 95.6 % | 0.76 [ 0.54, 1.07 ] |
| EORTC 2001 | 1/350 | 3/348 | | 4.4 % | 0.33 [ 0.03, 3.17 ] |
| Subtotal (95% CI) | 801 | 799 | | 100.0 % | 0.74 [ 0.53, 1.04 ] |

Total events: 51 (Treatment), 69 (Control)
Heterogeneity: Chi² = 0.50, df = 1 (P = 0.48); I² =0.0%
Test for overall effect: Z = 1.75 (P = 0.080)

| 3 Leucopenia/neutropenia/infections | | | | | |
|---|---|---|---|---|---|
| Bordeaux 1991 | 21/134 | 29/104 | | 16.7 % | 0.56 [ 0.34, 0.93 ] |
| EORTC 2001 | 38/350 | 46/348 | | 23.7 % | 0.82 [ 0.55, 1.23 ] |
| Institut Curie 1994 | 25/200 | 45/190 | | 23.7 % | 0.53 [ 0.34, 0.83 ] |
| NSABP 1998 | 54/748 | 69/725 | | 35.9 % | 0.76 [ 0.54, 1.07 ] |
| Subtotal (95% CI) | 1432 | 1367 | | 100.0 % | 0.69 [ 0.56, 0.84 ] |

Total events: 138 (Treatment), 189 (Control)
Heterogeneity: Chi² = 3.03, df = 3 (P = 0.39); I² =1%
Test for overall effect: Z = 3.61 (P = 0.00030)

| 4 Nausea and vomiting | | | | | |
|---|---|---|---|---|---|
| EORTC 2001 | 71/350 | 64/348 | | 74.9 % | 1.10 [ 0.81, 1.49 ] |
| Institut Curie 1994 | 22/200 | 21/190 | | 25.1 % | 1.00 [ 0.57, 1.75 ] |
| Subtotal (95% CI) | 550 | 538 | | 100.0 % | 1.08 [ 0.82, 1.41 ] |

Total events: 93 (Treatment), 85 (Control)
Heterogeneity: Chi² = 0.10, df = 1 (P = 0.75); I² =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)

| 5 Alopecia | | | | | |
|---|---|---|---|---|---|
| EORTC 2001 | 148/350 | 172/348 | | 25.0 % | 0.86 [ 0.73, 1.01 ] |
| Institut Curie 1994 | 44/200 | 36/190 | | 5.4 % | 1.16 [ 0.78, 1.72 ] |
| NSABP 1998 | 491/748 | 472/725 | | 69.6 % | 1.01 [ 0.94, 1.09 ] |
| Subtotal (95% CI) | 1298 | 1263 | | 100.0 % | 0.98 [ 0.91, 1.05 ] |

Total events: 683 (Treatment), 680 (Control)
Heterogeneity: Chi² = 3.99, df = 2 (P = 0.14); I² =50%
Test for overall effect: Z = 0.63 (P = 0.53)

0.2　0.5　1　2　5
Favours treatment　　Favours control

コメント：　RCT4つの評価　有意な差を認める

| | Cochrane reviewに記載なし | |
|---|---|---|
| **Funnel plot** | | |
| | コメント: 異質性ない | |
| **その他の解析** | | コメント: |
| メタリグレッション | | |
| 感度分析 | | |

【4-9　メタアナリシス】

| CQ | 手術可能な浸潤性乳管癌に対して術前化学療法は推奨されるか？ | | |
|---|---|---|---|
| P | 手術可能な浸潤性乳管癌 | I | 術前化学療法 |
| C | 術後化学療法 | O | 心毒性 |

| 研究デザイン | RCT | 文献数 | 2 | コード | ECTO 2005, EORTC 2001, |
|---|---|---|---|---|---|
| モデル | ランダム効果 | 方法 | | Cochrane Review Manager Software（RevMan 4.2） | |
| 効果指標 | リスク比 | 統合値 | | 0.74（　0.53　－　1.04　）P=　0.080 | |

Forest plot

| Study or subgroup | Treatment n/N | Control n/N | Risk Ratio M-H,Fixed,95% CI | Weight | Risk Ratio M-H,Fixed,95% CI |
|---|---|---|---|---|---|
| 1 Postoperative complications | | | | | |
| Edinburgh 1995 | 7/40 | 7/39 | | 52.4 % | 0.98 [ 0.38, 2.52 ] |
| EORTC 2001 | 0/350 | 2/348 | | 18.5 % | 0.20 [ 0.01, 4.13 ] |
| USA 2003 | 4/26 | 4/27 | | 29.0 % | 1.04 [ 0.29, 3.72 ] |
| Subtotal (95% CI) | 416 | 414 | | 100.0 % | 0.85 [ 0.41, 1.76 ] |

Total events: 11 (Treatment), 13 (Control)
Heterogeneity: Chi² = 1.06, df = 2 (P = 0.59); I² =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)

| 2 Cardiotoxicity | | | | | |
|---|---|---|---|---|---|
| ECTO 2005 | 50/451 | 66/451 | | 95.6 % | 0.76 [ 0.54, 1.07 ] |
| EORTC 2001 | 1/350 | 3/348 | | 4.4 % | 0.33 [ 0.03, 3.17 ] |
| Subtotal (95% CI) | 801 | 799 | | 100.0 % | 0.74 [ 0.53, 1.04 ] |

Total events: 51 (Treatment), 69 (Control)
Heterogeneity: Chi² = 0.50, df = 1 (P = 0.48); I² =0.0%
Test for overall effect: Z = 1.75 (P = 0.080)

| 3 Leucopenia/neutropenia/infections | | | | | |
|---|---|---|---|---|---|
| Bordeaux 1991 | 21/134 | 29/104 | | 16.7 % | 0.56 [ 0.34, 0.93 ] |
| EORTC 2001 | 38/350 | 46/348 | | 23.7 % | 0.82 [ 0.55, 1.23 ] |
| Institut Curie 1994 | 25/200 | 45/190 | | 23.7 % | 0.53 [ 0.34, 0.83 ] |
| NSABP 1998 | 54/748 | 69/725 | | 35.9 % | 0.76 [ 0.54, 1.07 ] |
| Subtotal (95% CI) | 1432 | 1367 | | 100.0 % | 0.69 [ 0.56, 0.84 ] |

Total events: 138 (Treatment), 189 (Control)
Heterogeneity: Chi² = 3.03, df = 3 (P = 0.39); I² =1%
Test for overall effect: Z = 3.61 (P = 0.00030)

| 4 Nausea and vomiting | | | | | |
|---|---|---|---|---|---|
| EORTC 2001 | 71/350 | 64/348 | | 74.9 % | 1.10 [ 0.81, 1.49 ] |
| Institut Curie 1994 | 22/200 | 21/190 | | 25.1 % | 1.00 [ 0.57, 1.75 ] |
| Subtotal (95% CI) | 550 | 538 | | 100.0 % | 1.08 [ 0.82, 1.41 ] |

Total events: 93 (Treatment), 85 (Control)
Heterogeneity: Chi² = 0.10, df = 1 (P = 0.75); I² =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)

| 5 Alopecia | | | | | |
|---|---|---|---|---|---|
| EORTC 2001 | 148/350 | 172/348 | | 25.0 % | 0.86 [ 0.73, 1.01 ] |
| Institut Curie 1994 | 44/200 | 36/190 | | 5.4 % | 1.16 [ 0.78, 1.72 ] |
| NSABP 1998 | 491/748 | 472/725 | | 69.6 % | 1.01 [ 0.94, 1.09 ] |
| Subtotal (95% CI) | 1298 | 1263 | | 100.0 % | 0.98 [ 0.91, 1.05 ] |

Total events: 683 (Treatment), 680 (Control)
Heterogeneity: Chi² = 3.99, df = 2 (P = 0.14); I² =50%
Test for overall effect: Z = 0.63 (P = 0.53)

0.2　0.5　1　2　5
Favours treatment　　Favours control

コメント：　RCT2つで評価　有意な差なし

| | |
|---|---|
| **Funnel plot** | Cochrane reviewに記載なし |
| | コメント： 異質性なし |

| その他の解析 | | コメント： |
|---|---|---|
| メタリグレッション | | |
| 感度分析 | | |

【4-9　メタアナリシス】

| CQ | 手術可能な浸潤性乳癌に対して術前化学療法は推奨されるか？ | | |
|---|---|---|---|
| P　手術可能な浸潤性乳癌 | | I | 術前化学療法 |
| C　術後化学療法 | | O | 乳房温存率の向上 |
| 研究デザイン | RCT | 文献数　10 | コード | ABCSG2001, Bordeaux 1991, ECTO 2005, EORTC 2001, Institut Curie 1991, Institut Curie 1994, London 2001, NSABP 1998, Royal Marsden 1998, St. Petersburg 1994, USA 2003 |
| モデル | ランダム効果 | 方法 | Cochrane Review Manager Software (RevMan 4.2) |
| 効果指標 | リスク比 | 統合値 | 0.71（　　0.67　−　　0.75　）P=　＜0.00001 |

**Forest plot**

| Study or subgroup | Treatment n/N | Control n/N | Risk Ratio M-H,Fixed,95% CI | Weight | Risk Ratio M-H,Fixed,95% CI |
|---|---|---|---|---|---|
| ABCSG 2001 | 71/214 | 85/209 | | 6.5 % | 0.82 [ 0.63, 1.05 ] |
| Bordeaux 1991 | 74/134 | 136/136 | | 10.3 % | 0.55 [ 0.48, 0.65 ] |
| ECTO 2005 | 154/438 | 579/875 | | 29.3 % | 0.53 [ 0.46, 0.61 ] |
| EORTC 2001 | 203/323 | 262/341 | | 19.3 % | 0.82 [ 0.74, 0.91 ] |
| Institut Curie 1991 | 22/95 | 31/86 | | 2.5 % | 0.64 [ 0.40, 1.02 ] |
| Institut Curie 1994 | 73/200 | 66/190 | | 5.1 % | 1.05 [ 0.80, 1.37 ] |
| London 2001 | 11/100 | 9/110 | | 0.6 % | 1.34 [ 0.58, 3.11 ] |
| NSABP 1998 | 239/743 | 302/752 | | 22.8 % | 0.80 [ 0.70, 0.92 ] |
| Royal Marsden 1998 | 16/149 | 31/144 | | 2.4 % | 0.50 [ 0.29, 0.87 ] |
| USA 2003 | 15/26 | 16/27 | | 1.2 % | 0.97 [ 0.62, 1.53 ] |
| **Total (95% CI)** | **2422** | **2870** | | **100.0 %** | **0.71 [ 0.67, 0.75 ]** |

Total events: 878 (Treatment), 1517 (Control)
Heterogeneity: Chi² = 53.43, df = 9 (P<0.00001); I² =83%
Test for overall effect: Z = 10.92 (P < 0.00001)
Test for subgroup differences: Not applicable

0.2　0.5　1　2　5
Favours treatment　　Favours control

コメント：　乳房切除率を評価しており、有意に低下している

**Funnel plot**

SE(log RR)

RR (fixed)

コメント：　symmetrical distributionであるが異質性ありと判断
Heterogeneity: Chi2 = 53.43, df = 9 (P<0.00001); I2 =83%
異質性の高い2つの試験を除いた評価でも、乳房切除率は有意に低下している（その他の解析を参照）

| Study or subgroup | Treatment n/N | Control n/N | Risk Ratio M-H,Fixed,95% CI | Weight | Risk Ratio M-H,Fixed,95% CI |
|---|---|---|---|---|---|
| **1 Included** | | | | | |
| ABCSG 2001 | 71/214 | 85/209 | | 6.5 % | 0.82 [ 0.63, 1.05 ] |
| EORTC 2001 | 203/323 | 262/341 | | 19.3 % | 0.82 [ 0.74, 0.91 ] |
| Institut Curie 1991 | 22/95 | 31/86 | | 2.5 % | 0.64 [ 0.40, 1.02 ] |
| Institut Curie 1994 | 73/200 | 66/190 | | 5.1 % | 1.05 [ 0.80, 1.37 ] |
| London 2001 | 11/100 | 9/110 | | 0.6 % | 1.34 [ 0.58, 3.11 ] |
| NSABP 1998 | 239/743 | 302/752 | | 22.8 % | 0.80 [ 0.70, 0.92 ] |
| Royal Marsden 1998 | 16/149 | 31/144 | | 2.4 % | 0.50 [ 0.29, 0.87 ] |
| USA 2003 | 15/26 | 16/27 | | 1.2 % | 0.97 [ 0.62, 1.53 ] |
| **Subtotal (95% CI)** | **1850** | **1859** | | **60.4 %** | **0.82 [ 0.76, 0.89 ]** |
| Total events: 650 (Treatment), 802 (Control) | | | | | |
| Heterogeneity: Chi² = 9.43, df = 7 (P = 0.22); I² =26% | | | | | |
| Test for overall effect: Z = 5.10 (P < 0.00001) | | | | | |
| **2 Excluded** | | | | | |
| Bordeaux 1991 | 74/134 | 136/136 | | 10.3 % | 0.55 [ 0.48, 0.65 ] |
| ECTO 2005 | 154/438 | 579/875 | | 29.3 % | 0.53 [ 0.46, 0.61 ] |
| **Subtotal (95% CI)** | **572** | **1011** | | **39.6 %** | **0.54 [ 0.48, 0.60 ]** |
| Total events: 228 (Treatment), 715 (Control) | | | | | |
| Heterogeneity: Chi² = 0.18, df = 1 (P = 0.67); I² =0.0% | | | | | |
| Test for overall effect: Z = 11.31 (P < 0.00001) | | | | | |
| **Total (95% CI)** | **2422** | **2870** | | **100.0 %** | **0.71 [ 0.67, 0.75 ]** |
| Total events: 878 (Treatment), 1517 (Control) | | | | | |
| Heterogeneity: Chi² = 53.43, df = 9 (P<0.00001); I² =83% | | | | | |
| Test for overall effect: Z = 10.92 (P < 0.00001) | | | | | |
| Test for subgroup differences: Chi² = 39.46, df = 1 (P = 0.00), I² =97% | | | | | |

0.2    0.5    1    2    5

Favours treatment    Favours control